Hope for KRAS-G12D Lung Cancer
Memorial Sloan Kettering Cancer Center researchers have reported promising results from a first-of-its-kind clinical trial targeting the KRAS-G12D mutation in non-small cell lung cancer (NSCLC). The experimental drug zoldonrasib (RMC-9805) demonstrated significant tumor shrinkage in 61% of participants who had previously not responded to standard treatments. These findings offer hope for patients with this challenging mutation subtype.
